GSK plc (GSK.L) Stock Price

GSK plc Price

LSE·CLOSED
19.14GBP-0.18 (-0.91 %)
Market closed

Over the last 19 years GSK plc grew revenue by 1.8% annually, reaching 32.67 B GBP. Earnings per share have grown at 2.0% per year over the last 19 years. For GSK plc, the net margin of 17.5% is broadly stable versus 17.8% a few years ago. At today's price the dividend yield works out to roughly 4.39%. The dividend has grown at 2.4% per year over the past 19 years. The consensus 12-month price target for GSK plc is 1,861.50 GBP, about 9,625.7% above where the stock trades today. Of 32 analysts, 14 rate the stock a buy — an overall Hold consensus. The stock trades about 39% above its 52-week low.

GSK plc stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of GSK plc over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how GSK plc stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing GSK plc's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

GSK plc Stock Price History
DateGSK plc Price
8/4/202619.14 GBP
7/31/202619.32 GBP
7/30/202619.64 GBP
7/29/202620.07 GBP
7/28/202619.65 GBP
7/27/202619.61 GBP
7/24/202619.20 GBP
7/23/202619.00 GBP
7/22/202619.11 GBP
7/21/202618.93 GBP
7/20/202618.82 GBP
7/17/202618.82 GBP
7/16/202619.56 GBP
7/15/202619.17 GBP
7/14/202619.21 GBP
7/13/202619.56 GBP
7/10/202619.62 GBP
7/9/202619.60 GBP
7/8/202619.73 GBP
7/7/202620.03 GBP
7/6/202619.83 GBP
7/3/202620.01 GBP
7/2/202620.04 GBP
7/1/202619.30 GBP
6/30/202619.81 GBP
6/29/202619.80 GBP
6/26/202619.83 GBP
6/25/202619.84 GBP
6/24/202619.50 GBP
6/23/202619.58 GBP
6/22/202619.25 GBP
6/19/202619.39 GBP
6/18/202619.63 GBP
6/17/202619.46 GBP
6/16/202619.65 GBP
6/15/202619.76 GBP
6/12/202619.86 GBP
6/11/202619.35 GBP
6/10/202619.18 GBP
6/9/202619.04 GBP
6/8/202619.20 GBP
6/5/202619.20 GBP
6/4/202618.76 GBP
6/3/202618.22 GBP
6/2/202618.25 GBP
6/1/202618.74 GBP
5/29/202619.05 GBP
5/28/202619.27 GBP
5/27/202619.37 GBP
5/26/202619.25 GBP
5/22/202619.22 GBP
5/21/202619.08 GBP
5/20/202618.95 GBP
5/19/202619.02 GBP
5/18/202618.77 GBP
5/15/202618.63 GBP
5/14/202618.87 GBP
5/13/202618.86 GBP
5/12/202618.92 GBP
5/11/202618.45 GBP
5/8/202618.43 GBP
5/7/202618.73 GBP
5/6/202618.75 GBP
5/5/202618.57 GBP
5/1/202619.01 GBP
4/30/202619.29 GBP
4/29/202619.18 GBP
4/28/202620.28 GBP
4/27/202620.16 GBP
4/24/202620.20 GBP
4/23/202620.76 GBP
4/22/202620.75 GBP
4/21/202620.82 GBP
4/20/202621.44 GBP
4/17/202621.44 GBP
4/16/202621.23 GBP
4/15/202621.31 GBP
4/14/202621.90 GBP
4/13/202621.70 GBP
4/10/202621.76 GBP
4/9/202621.67 GBP
4/8/202621.25 GBP
4/7/202620.96 GBP
4/2/202621.44 GBP
4/1/202621.07 GBP
3/31/202620.64 GBP
3/30/202620.63 GBP
3/27/202620.49 GBP
3/26/202620.47 GBP
3/25/202620.54 GBP
3/24/202619.77 GBP
3/23/202619.37 GBP
3/20/202619.51 GBP
3/19/202619.56 GBP
3/18/202619.73 GBP
3/17/202620.13 GBP
3/16/202620.26 GBP
3/13/202620.31 GBP
3/12/202620.31 GBP
3/11/202620.66 GBP
3/10/202620.64 GBP
3/9/202620.46 GBP
3/6/202620.38 GBP
3/5/202620.76 GBP
3/4/202621.15 GBP
3/3/202621.22 GBP
3/2/202621.80 GBP
2/27/202622.01 GBP
2/26/202621.67 GBP
2/25/202622.14 GBP
2/24/202622.01 GBP
2/23/202622.06 GBP
2/20/202622.13 GBP
2/19/202622.26 GBP
2/18/202622.68 GBP
2/17/202622.39 GBP
2/16/202621.84 GBP
2/13/202621.65 GBP
2/12/202621.41 GBP
2/11/202621.50 GBP
2/10/202621.68 GBP
2/9/202621.59 GBP
2/6/202621.98 GBP
2/5/202621.80 GBP
2/4/202620.80 GBP
2/3/202619.46 GBP
2/2/202619.25 GBP
1/30/202618.77 GBP
1/29/202618.52 GBP
1/28/202618.18 GBP
1/27/202618.63 GBP
1/26/202618.29 GBP
1/23/202618.01 GBP
1/22/202618.05 GBP
1/21/202617.88 GBP
1/20/202617.96 GBP
1/19/202618.16 GBP
1/16/202618.17 GBP
1/15/202618.48 GBP
1/14/202618.81 GBP
1/13/202618.58 GBP
1/12/202618.77 GBP
1/9/202618.86 GBP
1/8/202618.91 GBP
1/7/202619.02 GBP
1/6/202619.00 GBP
1/5/202618.21 GBP
1/2/202618.32 GBP
12/31/202518.25 GBP
12/30/202518.31 GBP
12/29/202518.23 GBP
12/24/202518.06 GBP
12/23/202518.15 GBP
12/22/202518.10 GBP
12/19/202518.22 GBP
12/18/202518.13 GBP
12/17/202518.34 GBP
12/16/202518.20 GBP
12/15/202518.34 GBP
12/12/202518.25 GBP
12/11/202518.21 GBP
12/10/202518.04 GBP
12/9/202517.83 GBP
12/8/202518.21 GBP
12/5/202518.05 GBP
12/4/202518.26 GBP
12/3/202518.33 GBP
12/2/202518.19 GBP
12/1/202518.00 GBP
11/28/202517.91 GBP
11/27/202518.02 GBP
11/26/202518.14 GBP
11/25/202517.95 GBP
11/24/202517.94 GBP
11/21/202517.88 GBP
11/20/202517.61 GBP
11/19/202517.73 GBP
11/18/202517.87 GBP
11/17/202518.00 GBP
11/14/202517.84 GBP
11/13/202518.11 GBP
11/12/202518.24 GBP
11/11/202518.25 GBP
11/10/202517.72 GBP
11/7/202517.69 GBP
11/6/202517.79 GBP
11/5/202517.88 GBP
11/4/202517.90 GBP
11/3/202517.57 GBP
10/31/202517.81 GBP
10/30/202517.83 GBP
10/29/202517.52 GBP
10/28/202516.44 GBP
10/27/202516.40 GBP
10/24/202516.20 GBP
10/23/202516.47 GBP
10/22/202516.53 GBP
10/21/202516.46 GBP
10/20/202516.34 GBP
10/17/202516.25 GBP
10/16/202516.34 GBP
10/15/202516.28 GBP
10/14/202516.38 GBP
10/13/202516.28 GBP
10/10/202516.25 GBP
10/9/202516.40 GBP
10/8/202516.21 GBP
10/7/202516.15 GBP
10/6/202516.16 GBP
10/3/202516.29 GBP
10/2/202516.47 GBP
10/1/202516.72 GBP
9/30/202515.75 GBP
9/29/202515.18 GBP
9/26/202514.86 GBP
9/25/202514.71 GBP
9/24/202514.85 GBP
9/23/202514.94 GBP
9/22/202515.11 GBP
9/19/202514.97 GBP
9/18/202514.73 GBP
9/17/202514.74 GBP
9/16/202514.63 GBP
9/15/202514.79 GBP
9/12/202515.04 GBP
9/11/202515.18 GBP
9/10/202514.88 GBP
9/9/202514.91 GBP
9/8/202514.65 GBP
9/5/202514.76 GBP
9/4/202514.69 GBP
9/3/202514.68 GBP
9/2/202514.43 GBP
9/1/202514.48 GBP
8/29/202514.53 GBP
8/28/202514.60 GBP
8/27/202514.77 GBP
8/26/202514.70 GBP
8/22/202514.80 GBP
8/21/202514.93 GBP
8/20/202514.83 GBP
8/19/202514.52 GBP
8/18/202514.39 GBP
8/15/202514.25 GBP
8/14/202514.15 GBP
8/13/202514.35 GBP
8/12/202514.05 GBP
8/11/202514.04 GBP
8/8/202513.96 GBP
8/7/202513.83 GBP
8/6/202513.73 GBP
8/5/202513.97 GBP
Access this data via the Eulerpool API
Get Free API Key

GSK plc Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
30.33 B GBP
8.30 B GBP
4.93 B GBP
Jan 1, 2024
31.38 B GBP
8.14 B GBP
2.58 B GBP
Jan 1, 2025
32.67 B GBP
8.98 B GBP
5.72 B GBP
Jan 1, 2026 (e)
33.86 B GBP
9.35 B GBP
7.35 B GBP
Jan 1, 2027 (e)
35.62 B GBP
9.83 B GBP
8.01 B GBP
Jan 1, 2028 (e)
36.76 B GBP
10.15 B GBP
8.40 B GBP
Jan 1, 2029 (e)
38.33 B GBP
10.58 B GBP
8.91 B GBP
Jan 1, 2030 (e)
37.85 B GBP
10.45 B GBP
9.06 B GBP

GSK plc Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 5:28 AM
 
REVENUEB GBP
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB GBP
EBITB GBP
EBIT MARGIN%
NET INCOMEB GBP
NET INCOME GROWTH%
DIV.GBP
DIV. GROWTH%
SHARESB
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
27.8930.1930.8233.7524.3524.7029.3230.3331.3832.6733.8635.6236.7638.3337.8538.58
16.588.242.109.52-27.851.4018.743.423.464.113.655.213.194.27-1.251.93
68.0969.1368.9469.8869.9467.5871.1372.4271.9072.6772.6772.6772.6772.6772.6772.67
18.9920.8721.2523.5917.0316.6920.8621.9722.5623.7424.6125.8926.7127.8527.5028.03
7.047.998.368.885.995.758.408.308.148.989.359.8310.1510.5810.45–
25.2626.4627.1326.3224.6123.2828.6327.3825.9327.4727.6027.6027.6127.6127.61–
0.911.533.624.655.754.3914.964.932.585.727.358.018.408.919.068.12
-89.1767.98136.4928.2123.77-23.73241.07-67.05-47.75121.9828.529.054.866.071.71-10.40
95.000.800.800.800.800.8056.000.560.610.8468.0068.0068.00–––
10,574.16-99.16––––6,900.00-99.008.9337.707,995.24–––––
3.933.953.984.014.034.054.084.114.144.124.124.124.124.124.124.12
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales GSK plc generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue GSK plc retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare GSK plc's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares GSK plc has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against GSK plc's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

GSK plc stock margins

The GSK plc margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GSK plc. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GSK plc.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
67.58 %
23.28 %
17.76 %
Jan 1, 2022
71.13 %
28.63 %
51.00 %
Jan 1, 2023
72.42 %
27.38 %
16.25 %
Jan 1, 2024
71.90 %
25.93 %
8.21 %
Jan 1, 2025
72.67 %
27.47 %
17.50 %
Jan 1, 2026 (e)
72.67 %
27.61 %
21.70 %
Jan 1, 2027 (e)
72.67 %
27.61 %
22.49 %
Jan 1, 2028 (e)
72.67 %
27.61 %
22.85 %

GSK plc Stock Revenue, EBIT, Earnings per Share

The GSK plc earnings per share therefore indicates how much revenue GSK plc has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
6.09 GBP
1.42 GBP
1.08 GBP
Jan 1, 2022
7.18 GBP
2.06 GBP
3.66 GBP
Jan 1, 2023
7.38 GBP
2.02 GBP
1.20 GBP
Jan 1, 2024
7.58 GBP
1.96 GBP
0.62 GBP
Jan 1, 2025
7.93 GBP
2.18 GBP
1.39 GBP
Jan 1, 2026 (e)
8.22 GBP
2.27 GBP
1.78 GBP
Jan 1, 2027 (e)
8.65 GBP
2.39 GBP
1.95 GBP
Jan 1, 2028 (e)
8.93 GBP
2.46 GBP
2.04 GBP

GSK plc business model & stock analysis

GSK plc Segments

GSK plc Revenue by Segment (1/4)

  • 3 Years

  • Max

Commercial Operations
Specialty Medicine
Specialty Medicines
General Medicines
HIV, oncology, immuno-inflammation, respiratory and other
Vaccines
Meningitis, influenza, shingles, established vaccines
Sub Total
Vaccines [member]
Respiratory
Respiratory [member]
HIV
HIV [member]
Shingles
Other General Medicines
Established Vaccines
Established Vaccines [member]
Respiratory/Immunology and Other
Shingles [member]
Immuno inflammation respiratory and other
Meningitis
RSV
Meningitis [member]
Pandemic
Oncology
Influenza [member]
Influenza
Pandemic Vaccines
Details
Date
Commercial Operations
Specialty Medicine
Specialty Medicines
General Medicines
HIV, oncology, immuno-inflammation, respiratory and other
Vaccines
Meningitis, influenza, shingles, established vaccines
Sub Total
Vaccines [member]
Respiratory
Respiratory [member]
HIV
HIV [member]
Shingles
Other General Medicines
Established Vaccines
Established Vaccines [member]
Respiratory/Immunology and Other
Shingles [member]
Immuno inflammation respiratory and other
Meningitis
RSV
Meningitis [member]
Pandemic
Oncology
Influenza [member]
Influenza
Pandemic Vaccines
Jan 1, 2021
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
Jan 1, 2022
29.32 B GBP
11.27 B GBP
0.00 GBP
10.12 B GBP
0.00 GBP
0.00 GBP
0.00 GBP
7.87 B GBP
7.94 B GBP
0.00 GBP
6.55 B GBP
0.00 GBP
5.75 B GBP
0.00 GBP
3.57 B GBP
0.00 GBP
3.09 B GBP
0.00 GBP
2.96 B GBP
2.61 B GBP
0.00 GBP
0.00 GBP
1.12 B GBP
2.31 B GBP
602.00 M GBP
714.00 M GBP
0.00 GBP
64.00 M GBP
Jan 1, 2023
0.00 GBP
0.00 GBP
10.24 B GBP
10.22 B GBP
10.20 B GBP
9.86 B GBP
9.71 B GBP
0.00 GBP
0.00 GBP
6.83 B GBP
0.00 GBP
6.44 B GBP
0.00 GBP
3.45 B GBP
3.40 B GBP
3.27 B GBP
0.00 GBP
3.03 B GBP
0.00 GBP
0.00 GBP
1.26 B GBP
1.24 B GBP
0.00 GBP
44.00 M GBP
731.00 M GBP
0.00 GBP
504.00 M GBP
150.00 M GBP

GSK plc Revenue by Segment (2/4)

  • Max

Commercial Operations
Details
Date
Commercial Operations
Jan 1, 2021
0.00 GBP
Jan 1, 2022
0.00 GBP
Jan 1, 2023
30.33 B GBP

GSK plc Revenue by Segment (3/4)

  • 3 Years

  • Max

Consumer Healthcare [member]
Details
Date
Consumer Healthcare [member]
Jan 1, 2021
0.00 GBP
Jan 1, 2022
0.00 GBP
Jan 1, 2023
0.00 GBP

GSK plc Revenue by Segment (4/4)

  • 3 Years

  • Max

Pharmaceuticals [member]
New And Speciality
Consumer Healthcare [member]
Sub Total
Vaccines [member]
Established Pharmaceuticals [member]
Respiratory [member]
HIV [member]
Established Vaccines [member]
Shingles [member]
Oral Care [member]
Pain Relief
Digestive Health and Other
Vitamins Minerals and Supplements
Respiratory Health
Meningitis [member]
Pandemic
Immuno inflammation [member]
Oncology
Influenza [member]
Pandemic Vaccines
Brands Divested
Details
Date
Pharmaceuticals [member]
New And Speciality
Consumer Healthcare [member]
Sub Total
Vaccines [member]
Established Pharmaceuticals [member]
Respiratory [member]
HIV [member]
Established Vaccines [member]
Shingles [member]
Oral Care [member]
Pain Relief
Digestive Health and Other
Vitamins Minerals and Supplements
Respiratory Health
Meningitis [member]
Pandemic
Immuno inflammation [member]
Oncology
Influenza [member]
Pandemic Vaccines
Brands Divested
Jan 1, 2021
17.73 B GBP
9.97 B GBP
9.61 B GBP
9.46 B GBP
6.78 B GBP
7.76 B GBP
2.86 B GBP
4.78 B GBP
2.97 B GBP
1.72 B GBP
2.73 B GBP
2.28 B GBP
1.80 B GBP
1.51 B GBP
1.13 B GBP
961.00 M GBP
958.00 M GBP
885.00 M GBP
489.00 M GBP
679.00 M GBP
447.00 M GBP
151.00 M GBP
Jan 1, 2022
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
Jan 1, 2023
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP
0.00 GBP

GSK plc Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

GSK plc historical P/E ratio, EBIT multiple, and P/S ratio

GSK plc annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

GSK plc shares outstanding

The number of shares of GSK plc was 4.12 B in 2025. This indicates how many shares GSK plc is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
4.05 B Stocks
Jan 1, 2022
4.08 B Stocks
Jan 1, 2023
4.11 B Stocks
Jan 1, 2024
4.14 B Stocks
Jan 1, 2025
4.12 B Stocks
Jan 1, 2026 (e)
4.12 B Stocks
Jan 1, 2027 (e)
4.12 B Stocks
Jan 1, 2028 (e)
4.12 B Stocks

GSK plc stock splits

In GSK plc's history, there have been no stock splits.

GSK plc Dividend History

37 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
202617.18GBPYTD—2×
Feb 19, 20260.18GBP↑ 12.5%1/2
May 14, 202617.00GBP↑ 9,344.4%2/2
20250.84GBP↑ 37.7%5×
Feb 20, 20250.16GBP↑ 6.7%1/5
Feb 21, 20250.20GBP↑ 25.0%2/5
May 15, 20250.16GBP↓ 20.0%3/5
Aug 14, 20250.16GBP 0.0%4/5
Nov 13, 20250.16GBP 0.0%5/5
20240.61GBP↑ 9.4%4×
20230.56GBP↓ 16.8%4×
20220.67GBP↓ 16.3%4×
20210.80GBP 0.0%4×
20200.80GBP 0.0%4×
20190.80GBP 0.0%4×
20180.80GBP 0.0%4×
20170.80GBP 0.0%4×

GSK plc dividend history and estimates

In 2025, GSK plc paid a dividend amounting to 0.84 GBP. Dividend means that GSK plc distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.80 GBP
0.00 GBP
Jan 1, 2022 (e)
0.67 GBP
55.33 GBP
Jan 1, 2023
0.56 GBP
0.00 GBP
Jan 1, 2024
0.61 GBP
0.00 GBP
Jan 1, 2025 (e)
0.00 GBP
0.84 GBP
Jan 1, 2026 (e)
17.00 GBP
51.00 GBP
Jan 1, 2027 (e)
0.00 GBP
68.00 GBP
Jan 1, 2028 (e)
0.00 GBP
68.00 GBP

GSK plc dividend payout ratio

In 2025, GSK plc had a payout ratio of 4,609.62%. The payout ratio indicates the percentage of the company's profits that GSK plc distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
9,259.26 %
Jan 1, 2022
2,083.33 %
Jan 1, 2023
4,650.87 %
Jan 1, 2024
4,986.33 %
Jan 1, 2025
4,609.62 %
Jan 1, 2026 (e)
3,810.48 %
Jan 1, 2027 (e)
3,494.46 %
Jan 1, 2028 (e)
3,332.68 %

Current GSK plc forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.35 %
Buy
43.75 % (14)
Hold
43.75 % (14)
Sell
12.50 % (4)
12M Price Target
18.62
Last Price
19.14
Currency
GBP
12M Return Potential
-2.74 %
LTM Return
0 %

GSK plc Analyst Rating Actions

DateFirmActionRatingReliability
3/23/2021
SVB Leerink
SVB Leerink
DowngradeOutperformPerform–
2/4/2021
Deutsche Bank
Deutsche Bank
DowngradeHoldSell–
1/15/2021
Deutsche Bank
Deutsche Bank
MaintainedHold–
11/21/2019
UBS
UBS
UpgradeNeutralBuy51

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

GSK plc Earnings Calls

2025

GSK plc Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/24/20240.36GBP-7.29 BGBP-2024 Q1
1/31/20240.32GBP-7.75 BGBP-2023 Q4
2/1/20230.26GBP-7.48 BGBP-2022 Q4
11/2/20220.41GBP-7.44 BGBP-2022 Q3
7/27/20220.30GBP-6.60 BGBP-2022 Q2
4/27/20220.39GBP-9.13 BGBP-2022 Q1
2/9/20220.32GBP-9.64 BGBP-2021 Q4
10/27/20210.37GBP-8.86 BGBP-2021 Q3
7/28/20210.26GBP-7.67 BGBP-2021 Q2
4/28/20210.28GBP-8.00 BGBP-2021 Q1
...

EESG©

Eulerpool ESG Scorecard© for the GSK plc stock

88/100
83
Environment
96
Social
85
Governance
E

Environment

20
Scope 1 - Direct Emissions521,000
Scope 2 - Indirect emissions from purchased energy234,000
Scope 3 - Indirect emissions within the value chain4,640,000
Total CO₂ emissions755,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides—
Palm Oil
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees48
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

GSK plc shareholder structure

% Name
3.05956%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.02486%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.70719%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.46997%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
1.37731%
BlackRock Investment Management (UK) Ltd.
BlackRock Investment Management (UK) Ltd.
1.33483%
Wellington Management Company, LLP
Wellington Management Company, LLP
...

GSK plc Beneficial Ownership Filings (SEC 13D/G)

Free Float
96.9%
Float Shares
-
Shares Outstanding
-

GSK plc Executives and Management Board

23 members · avg. age 61 · 48 % women

DW

Dame Emma Walmsley (55)

Chief Executive Officer, Executive Director · since 2011

10.56 M GBP

Management

Ms. Julie Brown

Ms. Julie Brown (62)

Chief Financial Officer, Executive Director · since 2023

4.17 M GBP
DR

Mr. David Redfern (58)

President - Corporate Development

–
RS

Mr. Regis Simard

President - Global Supply Chain

–
PT

Mr. Phil Thomson

President - Global Affairs

–
DW

Ms. Deborah Waterhouse

Chief Executive Officer, ViiV Healthcare and President - GSK Global Health

–
DC

Ms. Diana Conrad

Chief People Officer

–

Board of Directors

SS

Sir Jonathan Symonds (65)

Independent Non-Executive Chairman of the Board

781,000.00 GBP
Dr. Hal Barron

Dr. Hal Barron (62)

Non-Executive Director · since 2018

462,000.00 GBP
CB

Mr. Charles Bancroft (65)

Senior Independent Non-Executive Director

333,000.00 GBP
HD

Dr. Harry Dietz (66)

Independent Non-Executive Director, Scientific and Medical Expert

275,000.00 GBP
AB

Dr. Anne Beal (62)

Independent Non-Executive Director

255,000.00 GBP
EA

Ms. Elizabeth Anderson (67)

Independent Non-Executive Director

206,000.00 GBP

GSK plc Supply Chain

GSK plc Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#NameTrend
1
Shionogi
Supplier·Customer·Pharmaceuticals·JP
0.72
0.28
-0.56
-0.53
0.35
0.64
2
Eli Lilly
Supplier·Customer·Pharmaceuticals·US
0.79
0.45
0.76
0.63
0.77
0.53
3
Harte-Hanks
Supplier·Media·US
0.54
0.03
0.65
0.38
0.51
0.48
4
UFlex
Supplier·IN
0.62
0.58
0.77
0.75
0.52
0.46
5
Aukett Swanke Group
Supplier·Professional Services·GB
—
-0.04
-0.95
-0.83
-0.28
0.38
#NameTrend
1
Farmacias Benavides B
Customer·N/A·MX
—
0.31
—
—
—
—
2
Talend SA
Supplier·FR
0.72
0.08
0.90
0.35
0.84
—
3
Roivant Sciences
Supplier·Customer·Pharmaceuticals·GB
0.70
0.75
-0.86
-0.56
-0.67
—
4
Innovid
Supplier·Media·US
0.65
0.73
-0.41
-0.22
-0.78
—
5
Cloudera, Inc.
Supplier·US
0.60
0.36
0.84
0.35
0.31
—

Frequently asked questions about GSK plc

Analysts currently set an average price target of 1,893.63 GBP for the GSK plc stock (median: 1,861.50 GBP), implying -1.1 % versus the latest price. The consensus is based on 32 analyst ratings.

GSK plc Analyst Price Targets 2026

32 analysts currently rate the GSK plc stock: 14 recommend buying, 14 holding and 4 selling. For 2026, analysts expect GSK plc to generate revenue of 33.86 B GBP and earnings per share of 1.78 GBP.

GSK plc Analyst Price Targets 2026

Converted at the current exchange rate, the GSK plc share trades at 22.33 EUR (19.14 GBP).

The GSK plc share (GSK.L) is listed on 4 stock exchanges, including: XETRA (GS7.DE), Frankfurt (GS71.F), London (GSK.L), SIX (Zürich) (GSK.SW).

No history available for GSK plc.

The expected revenue of GSK plc is 33.86 B GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of GSK plc is 7.35 B GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of GSK plc is currently 10.73. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the GSK plc stock.

The price-to-sales ratio (P/S) of GSK plc is currently 2.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the GSK plc stock.

The Eulerpool Quality Score for GSK plc is 5/10.

The ISIN of GSK plc is GB00BN7SWP63. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of GSK plc is 940561. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of GSK plc is GSK.L. The ticker symbol is used to trade GSK plc shares on the stock exchange.

Over the past 12 months, GSK plc paid a dividend of 0.84 GBP . This corresponds to a dividend yield of about 4.39 %. For the coming 12 months, GSK plc is expected to pay a dividend of 68.00 GBP.

The current dividend yield of GSK plc is 4.39 %.

GSK plc pays a dividend, distributed in the months of , , , .

GSK plc paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 68.00 GBP are expected. This corresponds to a dividend yield of 352.06 %.

GSK plc is assigned to the 'Health' sector.

In the year 2025, GSK plc distributed 82 GBP as dividends.

The dividends of GSK plc are distributed in GBP.

All fundamentals and in-depth analysis of GSK plc

Our stock analysis for GSK plc stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GSK plc. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

GSK plc Stock
GSK plc Revenue→
GSK plc Stock
GSK plc Net Income→
GSK plc Stock
GSK plc P/E→
GSK plc Stock
GSK plc P/S→
GSK plc Stock
GSK plc EBIT→
GSK plc Stock
GSK plc Dividend→
GSK plc Stock
GSK plc Directors Dealings→
GSK plc Stock
GSK plc Stocks→
GSK plc Stock
GSK plc Market capitalization→
GSK plc Stock
GSK plc Debt→
GSK plc Stock
GSK plc Liabilities→
GSK plc Stock
GSK plc Equity→
GSK plc Stock
GSK plc AAQS→
GSK plc Stock
GSK plc Employees→
GSK plc Stock
GSK plc ROE→
GSK plc Stock
GSK plc ROA→
GSK plc Stock
GSK plc ROCE→
GSK plc Stock
GSK plc News→
GSK plc Stock
GSK plc Analyst Price Targets→

Health Stocks

GT BiopharmaGrupa Modne ZakupyGuangdong Biolight Meditech CoGrifols SA ADRGuangdong Hybribio Biotech CoGrifolsGuangdong Jiaying Pharmaceutical CoGridAI TechnologiesGuangdong Kanghua Healthcare Group CoGRI BioGuangdong Lifestrong Pharmacy CoGreenwich LifesciencesAll Stocks A–Z →